Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

NCT04230954 is registered in ClinicalTrials.gov with University of South Alabama as lead sponsor.

NCT NCT04230954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04230954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Cabozantinib (XL184) Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
Lead sponsor
University of South Alabama
Phase
Phase 2
Overall status
Terminated
Start date
April 16, 2020
Completion date
February 16, 2022
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, metastatic cervical cancer, persistent cervical cancer, recurrent cervical cancer